Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

709.99 +8.57 (+1.22%)
Streaming Delayed Price Updated: 12:38 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
61 62 Next >
News headline image
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? ↗
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
News headline image
4 Dividend Stocks to Buy on the Pullback ↗
Take advantage of cheap prices 
Via The Motley Fool
News headline image
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Despite its impressive fundamentals,REGENERON PHARMACEUTICALS (NASDAQ:REGN) remains undervalued. ↗
REGENERON PHARMACEUTICALS has caught the attention as a great value stock. NASDAQ:REGN excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
News headline image
Top S&P500 movers in Wednesday's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Regeneron Shares Are Up Today: What's Going On? ↗
Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results. 
Via Benzinga
News headline image
These S&P500 stocks are moving in today's session ↗
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
News headline image
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗
Via The Motley Fool
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides ↗
Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth partnership. 
Via Benzinga
News headline image
Why Regeneron (REGN) Stock Is Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short... 
Via StockStory
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Which S&P500 stocks are gapping on Tuesday? ↗
Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session. 
Via Chartmill
News headline image
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday? ↗
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and... 
Via Benzinga
Topics Bonds
News headline image
Tuesday's pre-market session: top gainers and losers in the S&P500 index ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report ↗
Shares took a beating after Eylea sales came in light. Libtayo and Praluent also missed revenue forecasts. 
Via Investor's Business Daily
Topics Earnings Government
News headline image
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3%... 
Via StockStory
News headline image
Regeneron Reports First Quarter 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Insights into Regeneron Pharmaceuticals's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment. ↗
A fundamental analysis of (NASDAQ:REGN): Should Quality Investors Include NASDAQ:REGN in Their Portfolio? 
Via Chartmill
News headline image
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.